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 The colloquial phrase that urges a consumer to “talk to [their] doctor about [insert drug 
here]” is a hallmark of drug advertising.1  Television and print advertising are likely the most 
common media sources where consumers are exposed to that phrase.2  However, consumers are 
not exposed to these advertisements as aggressively on their social media platforms, but this is 
changing.3  This is likely due to a lingering challenge the Food and Drug Administration (FDA) 
has grappled with for direct-to-consumer (DTC) advertising of prescription drug products.4  
However, consumers are active about their health and over half of the United States population 
 
1 See, e.g., The Ambien Brand: Where Millions Have Turned When Having Trouble Falling 
Asleep, SANOFI (last visited July 1, 2020), https://www.ambien.com/.  
2 Joanne Kaufman, Think You’re Seeing More Drug Ads on TV? You Are, and Here’s Why, N.Y. 
TIMES (Dec. 24, 2017), https://www.nytimes.com/2017/12/24/business/media/prescription-
drugs-advertising-tv.html.  This is most likely a result of the existing regulations addressing 
broadcast, radio, and print mediums directly.  Prescription Drug Advertisements, 21 C.F.R. § 
202.1 (2019).   
3 Nitasha Tiku, Facebook has a Prescription: More Pharmaceutical Ads, WASH. POST (Mar. 4, 
2020), https://www.washingtonpost.com/technology/2020/03/03/facebook-pharma-ads/ (finding 
companies are beginning to ramp up their social media advertising). 
4 Direct-to-consumer (DTC) advertising is where a company advertises its product information to 
the consumer instead of healthcare professionals.  Direct-to-Consumer (DTC) Advertisements, 




has performed health research online.5  Thirty-seven percent of internet users specifically looked 
for information on prescription drugs.6  With these levels of consumer activism about their 
health, it is unsurprising to see a proliferation of DTC advertising to users on the Internet, and 
specifically placing these advertisements to social media.7 
In 2018, the pharmaceutical industry spent $6.1 billion on advertising, with $5.1 billion 
spent on television ads.8  In 2019, the healthcare and pharmaceutical industry spent $3.62 billion 
on digital advertising.9  As indicated by these figures, advertising is of immense scale.  With the 
advent of social media platforms, pharmaceutical companies could reach new and existing 
consumers through these new types of forums and media outlets.  However, this medium has 
remained in regulatory limbo since 2014—the last time the FDA issued a guidance document 
 
5 Most Internet Users Start at a Search Engine When Looking for Health Information Online, 
PEW RES. CTR. (Oct. 29, 2006), https://www.pewresearch.org/internet/2006/10/29/online-health-
search-2006/ (finding eighty percent of American internet users searched for health information).  
6 Id.  
7 See Tiku, supra note 3 (commenting industry is now beginning to advertise more heavily on 
social media). 
8 Alison Kanski, Nielsen: Pfizer Tops List of Biggest Pharma Advertisers in 2018, MED., MKTG, 
& MEDIA (Apr. 2, 2019), https://www.mmmonline.com/home/channel/nielsen-pfizer-tops-list-of-
biggest-pharma-advertisers-in-2018/. 




pertaining by name to social media.10  Enforcement against companies advertising prescription 
drugs using social media began with a warning letter issued in 2010 against Novartis 
Pharmaceuticals for developing a shareable Facebook widget.11  This letter highlighted an 
important theme for existing guidance and regulations— presentation of the risk information.12 
“Social media” describes a burgeoning set of platforms where people can share ideas and 
communicate with one another.13  User bases vary across platforms, with Facebook as a clear 
 
10 U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: INTERNET/SOCIAL MEDIA 
PLATFORMS: CORRECTING THIRD-PARTY MISINFORMATION ABOUT PRESCRIPTION DRUGS AND 
MEDICAL DEVICES (2014) [hereinafter THIRD-PARTY MISINFORMATION GUIDANCE]; U.S. FOOD 
& DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: INTERNET/SOCIAL MEDIA PLATFORMS WITH 
CHARACTER SPACE LIMITATIONS—PRESENTING RISK AND BENEFIT INFORMATION FOR 
PRESCRIPTION DRUGS AND MEDICAL DEVICES (2014) [hereinafter CHARACTER LIMIT GUIDANCE]. 




fViolationLetterstoPharmaceuticalCompanies/UCM221325.pdf (accessed May 23, 2020) 
[hereinafter Tasinga Warning Letter] (the Tasinga widget omitted the risk information). 
12 Id. at 2–4.  
13 See Social Media, BLACK’S LAW DICTIONARY (11th ed. 2019); Social Media, MERRIAM 
WEBSTER (last visited July 3, 2020).  Scholars have characterized applications from networking 
sites like Facebook to virtual game worlds like World of Warcraft are social media.  Andreas M. 
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leader with nearly two-and-a-half billion users.14  Some other familiar platforms like YouTube 
and Twitter have two billion and 386 million users, respectively.15  These high usage statistics 
also have a tremendous variance in the age of the user.16  Each of these platforms has a unique 
way of allowing users to interact and collaborate, and useful for businesses, targeted advertising 
services, which this Comment refers collectively as “functionality.”17   
 
Kaplan & Michael Haenlein, Users of the World, Unite! The Challenges and Opportunities of 
Social Media, 53 BUS. HORIZONS 59, 62 (2010). 
14 J. Clement, Most Popular Social Networks Worldwide as of April 2020, Ranked by Number of 
Active Users, STATISTA (Apr. 24, 2020), https://www.statista.com/statistics/272014/global-
social-networks-ranked-by-number-ofusers/ (also reporting other platforms, like TikTok and 
Snapchat have ascertained 800 million users and 398 million users respectively). 
15 Id. 
16 Social Media Fact Sheet, PEW RES. CTR. (last visited Aug. 21, 2020), 
https://www.pewresearch.org/internet/fact-sheet/social-media/ (finding that over fifty percent of 
individuals aged eighteen to sixty-five years old have at least one social media account).  
17 Facebook for Business, FACEBOOK (last visited Aug. 21, 2020), 
https://www.facebook.com/business/ads/ad-targeting; Twitter Ads Targeting, TWITTER (last 
visited Aug. 21, 2020), https://business.twitter.com/en/advertising/targeting.html.  For the 
purposes of this Comment, functionality also includes constraints in the ability to express and 
manifest an idea. See, e.g., “Tweet,” Glossary, TWITTER, https://help.twitter.com/en/glossary 
(last visited July 8, 2020) (where a tweet is limited to 280 characters and may contain photos and 
video content); “Single Image or Video Ads,” Snapchat Ad Specs, SNAPCHAT, 
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This Comment will explore how to address social media as a new medium for advertising 
in three parts.  Part I discusses the creation and evolution of the Food, Drug, and Cosmetics Act’s 
(FDCA’s) drug approval scheme and relevant statutory provisions for protecting the public 
health.  Part II discusses the guidance documents the FDA has issued on social media and 
discusses the weaknesses of each one.  It then includes a discussion of the critical First 
Amendment case law in the realm of drugs, with a comprehensive analysis of how one of the 
guidance documents would stand with the First Amendment jurisprudence if challenged.  
Finally, Part III offers guidance to the FDA for how it should consider social media functionality 
in its thinking.  It then offers practical methods for how the FDA could update existing guidance 
or issue new guidance and use its notice-and-comment rulemaking procedures to update existing 
provisions when approaching social media functionality and DTC prescription drug advertising.  
I. THE DEVELOPMENT AND PROVISIONS OF THE FDCA 
A. Development of the FDCA 
Congress took one of its first major steps to enhance food and drug regulation in 1906, 
when it created a criminal offense for individuals who were misbranding food and drugs.18  This 
 
https://businesshelp.snapchat.com/en-US/article/top-snap-specs (last visited July 8, 2020) (where 
ads may be single image or videos and last from three seconds to three minutes).   
18 Pub. L. No. 59-384 (1906).  See generally Jillian London, Tragedy, Transformation, and 
Triumph: Comparing the Factors and Forces that Led to the Adoption of the 1860 Adulteration 
Act in England and the 1906 Pure Food and Drug Act in the United States, 69 FOOD & DRUG 
L.J. 315. 327–29, 336–41 (2014) (comparing the factors leading to England and the United States 
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legislation, however, did not include evaluation requirements for safety and efficacy; a change 
that arrived over the next few decades.19  However, the legislation’s intent and purpose of 
protecting the public health persisted as food and drug regulation evolved.20  In 1906, a “drug” 
was “all medicines and preparations recognized in the United States Pharmacopoeia or National 
Formulary . . . to be used for the cure, mitigation, or prevention of disease either by man or other 
animals,” but was amended to include additional definitions of what a drug could be.21 
 
drug regulatory regimes); infra Part I(B) (explaining misbranding).  Present provisions on food 
and drug misbranding can be found at FDCA §§ 403, 502, 21 U.S.C §§ 343, 352 (2018). 
19 Pub. L. No. 59-384. 
20 See H.R. REP. NO. 2139, at 1–2 (1938) (commenting that the Food, Drug, and Cosmetic Act’s 
(FDCA’s) purpose “amplifies and strengthens the provisions designed to safeguard the public 
health and prevent deception . . . .”).  
21 Compare Pub. L. No. 59-384, § 6 (defining drug as “all medicines and preparations” 
recognized by the National Formulary (NF) to be used in the treatment of disease), with 21 
U.S.C. § 321(g)(1)–(2) (2018) (which includes, in part, medicines recognized in the NF, but adds 
the definition of a “counterfeit drug”), and 21 U.S.C. § 321(p) (2018) (where the drug definition 
describes a “new drug”).  See also Lewis A. Grossman, Food, Drugs, and Droods: A Historical 
Consideration of Definitions and Categories in American Food and Drug Law, 93 CORNELL L. 
REV. 1091, 1104–8, 1112–18 (2008) (exploring the differences between the definitions of “drug” 
in the 1906 Pure Food and Drug Act and the FDCA). 
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Congress members began drafting a replacement law beginning as early as 1933.22  
However, passage would come after a paradigmatic moment in 1937 when an estimated ninety 
people died as a result of the S. E. Massengill Company distributing more than 240 gallons of a 
drug containing deadly chemical.23  The replacement of the 1906 Act occurred in 1938 with the 
introduction of the FDCA on January 6, 1937.24  Senator Royal Copeland, urging the passage of 
a new law, emphasized the purpose of a new food and drug bill was to protect society from such 
tragedies.25  This major update included the beginning of what would evolve into the robust 
premarket review of drugs that exists today.26  The existing model for premarket review came 
after the Thalidomide crisis in Europe.27  Following the crisis, Representative Oren Harris of 
Arkansas proposed amendments to the FDCA in 1962.28  These amendments created the 
 
22 David F. Cavers, The Food, Drug, and Cosmetic Act of 1938: Its Legislative History and Its 
Substantive Provisions, 6 L. &  CONTEMP. PROBS. 2, 6 (1939). 
23 PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 642 (4th ed. 
2013); Cavers, supra note 22, at 20.  
24 Federal Food, Drug, and Cosmetic Act, S. 5, 75th Cong. (1937).  
25 83 CONG. REC. 6264 (1938). 
26 Federal Food, Drug, and Cosmetic Act, S. 5, 75th Cong., § 505 (1938).  See also Hutt, supra 
note 23, at 642 (noting that the process at this time functioned as a “notification” system).  
27 Hutt, supra note 23, at 642.  See generally Anita Bernstein, Formed by Thalidomide: Mass 
Torts as a False Cure for Toxic Exposure, 97 COLUM. L. REV. 2153 (1997). 
28 H.R. REP. NO. 87-2464, at 1–2 (1962).  Some additional objectives included factory 
inspections and new procedures to follow for testing new drugs.  Id. at 1–2. 
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comprehensive drug review process that exists today with the “[r]equirement that new drugs be 
shown to be effective as well as safe.”29  For prescription drugs, these amendments also 
conferred important authority to the FDA with control over the advertising of such products.30 
 This history is here to highlight an oft-cited objective for the FDA to serve as protector of 
the public health.31  Social media adds another dimension of complexity to the FDA’s pursuit of 
this objective.32  On the one hand, consumer deception is at the forefront.33  In a similar vein, 
DTC advertising on social media likely revives similar challenges the FDA faced when it first 
began regulating DTC ads.34  The other side of the equation involves the possibility of a direct 
 
29 Id. at 1.  See also FDCA § 505(b)(1)(A), 21 U.S.C. § 355(b)(1)(A) (2018) (requiring a 
manufacturer to prove whether the drug is safe and effective for intended use). 
30 Hutt, supra note 23, at 907.  
31 See, e.g., United States v. Caronia, 703 F.3d 149, 166 (2d Cir. 2012); Amarin Pharma, Inc. v. 
U.S. Food & Drug Admin., 119 F. Supp. 3d 196, 217 (S.D.N.Y. 2015); Wash. Legal Found. v. 
Friedman, 13 F. Supp. 2d 51, 57 (D.C. Cir. 1998). 
32 Social media presents variable functionality industry could use to interact and engage 
consumers.  Tiku, supra note 3 (finding companies are beginning to promote on social media). 
33 See THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 3 (commenting that third-
party content may be hazardous to public health); CHARACTER LIMIT GUIDANCE, supra note 10, 
at 5 (claiming that “truthful, accurate, non-misleading, and balanced product information” will 
best serve the public health).  
34 See Jacqueline West, National Marketing Gone Unintentionally Global: Direct-to-Consumer 
Advertising of Pharmaceutical Products and the Internet, 11 J. INT’L BUS. & L. 405, 412 (2012) 
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challenge to the very core of the drug approval process: an avenue that could lead to off-label 
promotion.35  Clear from the history, however, are that drugs come under close scrutiny and with 
this scrutiny comes an agency charged with monitoring the commercial posture taken by 
manufacturers on these products.36 
B. Labeling, Misbranding, and Advertising a Prescription Drug  
In the current model of the FDCA, several provisions directly address the rules regarding 
the labeling and advertising of a drug.37  Further, additional rules are outlined in the CFR to help 
expound on the expectations set by the FDA.38  The FDCA defines a label as “a display of 
written, printed, or graphic matter upon the immediate container of any article . . . .”39  It then 
 
(summarizing how the “brief summary” requirement was a challenge for the FDA for broadcast 
advertising).  
35 See infra Parts I(B), II(C) (defining off-label promotion and exploring the challenges courts 
have placed in the FDA’s path).  
36 See infra Part I(B) (covering the statutory and regulatory tools the FDA has to review the 
potential misbranding of a drug).  
37 See, e.g., FDCA §502(f), (n), 21 U.S.C. § 352(f), (n) (2018).  Inversely, the labeling 
requirements might be easy to understand by seeing what the labeling should avoid for fear of 
being deemed misbranded (a topic that will be discussed shortly).  See, e.g., § 352(a)(1) (“a drug 
. . . shall be deemed to be misbranded if its labeling is false or misleading in any particular”). 
38 21 C.F.R. §§ 201.1, 201.100, 202.1 (2019). 
39 FDCA § 201(k), 21 U.S.C. § 321(k). 
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classifies “labeling” to include “all labels and other written, printed, or graphic matter (1) upon 
any article or any of its containers or wrappers, or (2) accompanying such article.”40 
For enforcement and compliance with the FDCA, misbranding is a common cause of 
action.41  The FDCA grants the FDA many tools to make a case about an article being 
misbranded.42  One tool is section 201(n), which allows the FDA to review “not only 
representations made or suggested . . . but also the extent to which the labeling or advertising 
fails to reveal facts material . . . under the conditions of use . . . .”43  In Kordel v. United States, 
the Court gave the language of section 201(m) a very liberal construction, holding “it is the 
textual relationship that counts.”44  These two provisions plus Kordel are valuable for the FDA 
when determining a misbranding violation. 
 
40 FDCA § 201(m), 21 U.S.C. § 321(m). 
41 See, e.g., United States v. Evers, 643 F.2d 1043, 1044 (5th Cir. 1981) (suit against a physician 
for misbranding a drug when giving information about its use to his patients); Alberty Food 
Products v. United States, 194 F.2d 462, 463 (9th Cir. 1952) (literature distributed to prospective 
consumers failed to demonstrate, among other things, diseases the drug was intended to cure). 
42 FDCA §§ 201(n), 301(a)–(b), 502(a)(1), (n), 21 U.S.C §§ 321(n), 331(a)–(b), 352(a)(1), (n). 
43 FDCA § 201(n), 21 U.S.C. § 321(n). 
44 335 U.S. 345, 350 (1948) (finding articles and accompanying literature can “supplement” each 
other and no physical attachment to the article is necessary). 
11 
 
Section 502 of the FDCA is devoted specifically to drugs.45  Under this section, 
misbranding can occur when the “labeling is false or misleading in any particular.”46  Another 
form of misbranding occurs when a label fails to reveal material facts, for example, “adequate 
directions for use.”47  These adequate directions for use are defined as “directions for which the 
layman can use a drug safely and for the purposes for which it is intended.”48  These directions 
may be found inadequate because “of omission . . . or incorrect specification of (a) statements of 
all conditions, purposes, or uses for which such drug is intended . . . (b) quantity of dose . . . (c) 
frequency of administration . . . .”49 
A drug that is not approved for a specific use, under which there is no general recognition 
by scientists qualified to evaluate safety and efficacy of the drug for that use, is considered a 
“new drug.”50  Promoting a drug as such violates section 505(a) for “introduction into interstate 
commerce any new drug, unless approval of an application . . . is effective with respect to such 
 
45 FDCA § 502, 21 U.S.C. § 352. 
46 § 352(a)(1).  
47 FDCA §§ 201(n), 502(f)(1), 21 U.S.C. §§ 321(n), 352(f)(1). 
48 Labeling, 21 C.F.R. § 201.5 (2019).  For example, a failure to include how to properly prepare 
the drug for use could be found inadequate. § 201.5(g). 
49 § 201.5(a)–(c). The regulation also provides that other factors, like the method of 
administration and information about preparation, are some other possibilities. § 201.5(f), (g). 
50 FDCA § 201(p)(1), 21 U.S.C. § 321(p)(1). 
12 
 
drug.”51  This in conjunction with FDCA section 301(a), creates the prohibition against what is 
known as “off-label promotion” because promotion must be consistent with the FDA approved 
labeling.52  These prohibitions are important for social media considerations because if a firm is 
going to promote its product, it must do so in accord with the FDA approval of its product.53  
Failure to do so will likely result in a misbranding action taken by the FDA against the offending 
party.54 
The FDA recognizes several types of advertisements manufacturers may employ to 
promote their products.55  The main types of advertisements are “Product Claim” advertisements, 
“Reminder” advertisements, and “Help-seeking” advertisements.56  A “Product Claim” 
advertisement is one that names the drug and discusses the benefits and risks.57  In a print 
medium, these advertisements must include a “brief summary,” which includes all the known 
 
51 FDCA § 505(a), 21 U.S.C. § 355(a). The basic elements of what a new drug application looks 
like can be found under subsection (b)(1) of the same statute.  
52 FDCA § 301(a), 21 U.S.C. § 331(a).   
53 Id.  
54 See, e.g., United States v. Caronia, 703 F.3d 149, 157 (2d Cir. 2012) (one of the counts against 
Mr. Caronia was a conspiracy to introduce a drug into interstate commerce that was misbranded). 
55 Basics of Drug Ads, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/prescription-
drug-advertising/basics-drug-ads (last visited July 5, 2020). 
56 Id.  
57 Id.  This will be the most pivotal type of advertisement discussed by this Comment in Part III. 
13 
 
risks posed by the drug.58  If done through a broadcast medium, the advertisement must include a 
“major statement,” which is a communication of the most important risks and how viewers may 
locate more risk information.59  A “Reminder” advertisement does not disclose risk information, 
but simply provides the audience the name of the drug without including indications the drug is 
approved for.60  “Help-seeking” advertisements are interesting because when created “properly,” 
they are not supposed to be drug advertisements.61  These types of ads fall under the Federal 
Trade Commission’s (FTC’s) purview.62  Lastly, FDA states that “Other Product Claim 
Promotional Material” is “promotional labeling” and if these materials mention a drug’s benefits, 
they must also include the prescribing information.63  
 
58 FDCA § 502(n)(3), 21 U.S.C § 352(n)(3); Prescription Drug Advertisements, 21 C.F.R. § 
202.1(e)(1) (2019); Basics of Drug Ads, supra note 55.  The “brief summary” forbids advertisers 
from suggesting the use of the drug for an unapproved indication. § 202.1(e)(iii)(4)(i)(a).  
59 § 202.1(e)(1); Basics of Drug Ads, supra note 55.  The CFR provides that the major statement 
applies to broadcasts through radio, television, or telephone.  § 202.1(e)(1). 
60 § 202.1(e)(2)(i); Basics of Drug Ads, supra note 55.  Prescription drugs that contain boxed 
warnings in their labeling are prohibited from using these advertisements. § 202.1(e)(2)(i). 
61 Basics of Drug Ads, supra note 55. 
62 Id.  However, if they mention or suggest a specific drug, the FDA will retain purview. Id. 
63 Id.  The FDA defines “promotional labeling” as items distributed to consumers, like brochures 
and cups, among other things.  “Promotional Labeling,” Drug Advertising: A Glossary of Terms, 
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/prescription-drug-advertising/drug-
advertising-glossary-terms#P (last visited July 7, 2020). 
14 
 
These types of advertisements are important because each type comes with unique 
requirements.64  When considering these for social media functions, some may be better suited 
than others for certain mediums.65  If the advertisement form is a “Help-Seeking” advertisement, 
then the jurisdiction itself shifts from the FDA to the FTC, which can be a limitation on the 
FDA’s capacity to review an advertisement.66  An important challenge to consider with “Product 
Claim” advertisements are how social media functions can be used to navigate the “brief 
summary” requirement.67   
II. SOCIAL MEDIA GUIDANCE AND THE FIRST AMENDMENT 
A. FDA’s Social Media Guidance  
In furtherance of this statutory evolution as an arbiter of the public health, the 
Administrative Procedure Act (APA) creates a process the FDA must adhere to when 
promulgating new rules that carry the force of law.68  However, there is also an exemption for it 
to issue “interpretative rules, general statements of policy, or rules of agency organization, 
procedure, or practice.”69  It is precisely this exemption in the process that allows the FDA to 
 
64 See Basics of Drug Ads, supra note 55. 
65 The FDA acknowledges this for reminder advertisements because those ads do not require the 
same amount of disclosure.  CHARACTER LIMIT GUIDANCE, supra note 10, at 4.  
66 Basics of Drug Ads, supra note 55. 
67 FDCA § 502(n)(3), 21 U.S.C. § 352(n)(3) (2018). 
68 Administrative Procedure Act (APA), 5 U.S.C. § 553 (2018).  
69 APA, § 553(b)(A). 
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issue a guidance document, which consists of its thinking on a particular subject and how it 
believes case law and statute apply.70 
Although the FDA presently maintains two guidance documents with the term “social 
media” in the title, the agency has otherwise minimally addressed the subject.71  The two 
documents focus on two main points: (1) how the FDA believes firms should approach 
correcting misinformation disseminated by third parties and (2) how firms should approach using 
social media sites and advertising mediums with character constraints.72  Both of these 
documents draw their strength from similar roots—the labeling and misbranding provisions 
granted by the FDCA.73  Discussion of these documents in depth will demonstrate that the FDA 
is thematically concerned with the public health and making sure the public has the best 
information to make informed decisions related to their health.74  However, these guidance 
 
70 See, e.g., THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 1; CHARACTER LIMIT 
GUIDANCE, supra note 10, at 1. 
71 THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10; CHARACTER LIMIT GUIDANCE, 
supra note 10.  
72 THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10; CHARACTER LIMIT GUIDANCE, 
supra note 10.  
73 See THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 2–3; CHARACTER LIMIT 
GUIDANCE, supra note 10, at 2–3; see also supra Part I(B) (discussing the relevant provisions).  
74 THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 3; CHARACTER LIMIT 
GUIDANCE, supra note 10, at 5. 
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documents fall short of addressing the First Amendment case law and commercial speech 
protections in issuing these guidance documents, which will be important for future guidance.   
1. Third-Party Misinformation Guidance 
The third-party misinformation guidance suggests how firms “should respond, if they 
choose . . . to misinformation related to a firm’s own FDA-approved or -cleared products . . . 
when that information is created or disseminated by independent third parties.”75  The FDA 
recognizes that firms are “generally not responsible” for third-party content about their product, 
but could be if it “solicit[ed] or influence[d]” the content.76  Section four of the guidance 
indicates how firms should communicate a correction request.77  Among the suggestions, the 
FDA highlights firms be “non-promotional in nature” and “consistent with the FDA-required 
labeling for the product.”78 The FDA also suggests firms include the approved labeling in their 
communications.79  If the product is a prescription drug, it should be “supported by sufficient 
evidence, including substantial evidence.”80 
 
75 THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 1 (emphasis added).  
76 Id. at 5. 
77 Id. at 5–6. 
78  Id.  
79 Id. at 6. 
80 Id.  “Substantial evidence” means “adequate and well-controlled investigations . . . to evaluate 
the effectiveness of the drug” FDCA § 505(d), 21 U.S.C. § 355(d) (2018). 
17 
 
The FDA recognizes the challenge that exists in trying to correct an entire forum due to 
the vast amount of information.81  The FDA does not expect a firm to seek to correct every piece 
of information that exists on a particular site.82  If a firm elects to correct some of the 
misinformation, it should “clearly identify the misinformation it is correcting, define the portion 
of the forum . . . and should correct all the misinformation that appears in that clearly defined 
portion.”83  However, a firm may not correct only some of the misinformation in a defined 
section; it must address it all.84  In addressing the defined section, the FDA offers several 
suggestions.85  Some of the methods include directly correcting the misinformation on the forum, 
providing corrective information to the author, requesting removal of the post, or contacting a 
site administrator.86  If the posts cannot be removed, the FDA requests firms keep records about 
its efforts addressing the misinformation.87 
 
81 THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 6.  
82 Id. at 7. 
83 Id.  
84 For example, if the firm chooses to correct information that negatively publicizes its product 
and ignores a clear overstatement of the product’s benefits in the same defined section, the firm 
has failed to adhere to the guidance.  Id.  
85 Id. at 7–8. 
86 Id. 
87 Id. at 9. 
18 
 
With all guidance documents, they are merely suggestions with no force of law and offer, 
at best as the name suggests, guidance on a topic.88  Dodging enforcement action, however, is 
valuable to a firm, so these documents do come with some bite.89  One of the challenging 
elements of this guidance is that, if a firm chooses to engage in correcting misinformation, it 
should do so in a manner that narrowly limits itself to the specific element that is creating the 
misinformation.90  This creates a content-based burden, which could prove problematic if the 
FDA is going to suggest a limit to a firm’s ability to respond to misinformation.91  Additionally, 
it offers that a firm not be “promotional in nature or tone,” which suggests a speaker-based 
burden, which is subject to a rigorous review under existing case law.92   
2. Character Limit Guidance 
The character limit guidance applies to a firm presenting the benefit information of its 
drug and stating it should also incorporate the risk information of it in “electronic/digital 
 
88 FDCA § 701(h)(1)(A), 21 U.S.C. § 371(h)(1)(A) (2018); see also Hutt, supra note 23, at 30 
(highlighting how the FDA has increasingly used this tool).  
89 See generally Lars Noah, Governance by the Backdoor: Administrative Law(lessness?) at the 
FDA, 93 NEB. L. REV. 89, 122–24 (2014) (surveying the value of compliance with guidance).  
90 See, e.g., THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 6 (where example 5 
discusses that information should be limited to the indication in question); see also infra Part 
II(B)(1) (discussing burdens on speech and applicable case law).  
91 See Sorrell v. IMS Health, Inc., 564 U.S. 552, 581 (2011) (“content-based burdens on 
protected expression are sufficient to justify an application of heightened scrutiny”).   
92 Sorrell, 564 U.S. at 572; THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 5. 
19 
 
platforms that are associated with character space limitations—specifically on the Internet and 
through social media . . . .”93  The document provides two mediums for examples, namely 
Twitter’s “tweet” and Google’s sponsored link service.94  It is not intended to apply to 
promotions on “product websites” or webpages that appear on social media (like product pages 
on Facebook, Twitter, or YouTube) because the FDA believes the same constraints do not 
exist.95   
In a character-limited platform, if a firm presents the benefit information, it should also 
discuss the risks.96  In presenting these two elements, the presentation should be of comparable 
“content and prominence.”97  Additionally, the FDA advises firms to provide a link to a place 
where a “more complete discussion” of the risk information.98  The guidance further highlights 
when crafting an advertisement or promotional statement, the “benefit information should be 
accurate and non-misleading and reveal material facts within . . . .”99  
 
93 CHARACTER LIMIT GUIDANCE, supra note 10, at 1. 
94 Id. at 1–2. 
95 Id. at 2. 
96 CHARACTER LIMIT GUIDANCE, supra note 10, at 5. 
97 Id. at 4; see also Prescription Drug Advertisements, 21 C.F.R. § 202.1(e)(5)(ii) (2019) 
(requiring the information be presented as a fair balance). 
98 CHARACTER LIMIT GUIDANCE, supra note 10, at 5. 
99 Material facts are about the use could be limitations to an indication or relevant population for 
treatment. Id. at 6.  
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The FDA offers two factors to evaluate the comparability in presentation of the risk 
versus the benefit: (1) whether the risk qualifies a representation about the product and (2) 
whether the risk has the same prominence and readability as the benefit information.100  At a 
minimum, the FDA suggests “the most serious risks associated with the product” be 
communicated.101  For prescription drugs, “the most serious risks” are those in a “boxed 
warning,” either fatal or life-threatening, or all contraindications found within the approved 
labeling.102  When providing a mechanism to communicate information beyond the tweet, the 
FDA suggests a “direct” hyperlink to a page that is “devoted exclusively to comprehensive risk 
information . . . .”103 
To help emphasize the comparability of the risk and benefit disclosures, the FDA 
suggests firms use the same emphasis that highlights the benefit information on the risk 
 
100 Id. at 8. 
101 Id. at 9. 
102 Id.  A “boxed warning” is a warning that a drug “may lead to death or serious injury . . . .”  
Labeling, 21 C.F.R. § 201.57(c)(1) (2019).  A “contraindication” is a condition when the drug 
“should not be used . . . .” “Contraindication,” MEDLINEPLUS, 
https://medlineplus.gov/ency/article/002314.htm (last visited July 21, 2020). 
103 Some examples of direct information offered are “landing pages” with information 
exclusively focused on risks or a PDF outlining the information. CHARACTER LIMIT GUIDANCE, 
supra note 10, at 10.  Firms may use URL condensing services to help fit the information. 
CHARACTER LIMIT GUIDANCE, supra note 10, at 10. 
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information as well.104  If the medium offers the ability to accentuate or reformat specific parts of 
the message, the FDA advises firms to use that formatting to highlight significant risk 
information.105  In formulation of the messages, the FDA permits the use of commonly utilized 
acronyms and symbols to assist with shrinking the size of the message to permit the balance of 
benefits and risks.106 
While these guidance documents begin tackling social media to ensure drugs are 
characterized in a consistent and balanced manner, they leave room for improvement.  An 
important shortcoming of the character limit guidance is its failure to explore the First 
Amendment jurisprudence in suggesting certain manufacturers avoid using those character-
limited platforms.107  This is further exacerbated since the suggestions made by the FDA create a 
speaker-based burden that suggests manufacturers try to comply with rigid requirements in a 
 
104 Id. at 10–11.  
105 For prescription drug messages, one example is reformatting a boxed warning for more 
prominence.  Id. at 11.  
106 Id. at 14.  
107 Industry highlights this case in its comments.  See Washington Legal Foundation, Comment 
Letter Concerning Draft Guidance for Industry on Internet/Social Media Platforms with Space 
Character Limitations, 4–6 (Sept. 16, 2014), https://www.regulations.gov/document?D=FDA-
2014-D-0397-0019 [hereinafter WLF Letter]; Medical Information Working Group, Draft 
Guidance for Industry: Internet/Social Media Platforms with Character Space Limitations 
(Docket No. FDA-2014-D-0397), 4–5 (Sept. 16, 2014) [hereinafter MIWG Letter]. 
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narrowly defined space.108  While leveraging how the failure to reveal material facts could lead 
to the misbranding of a drug, the guidance does not clearly demonstrate a nexus as to how a 
consumer is more likely to be misled by an advertisement on this platform.109  A larger takeaway 
is that both guidance documents do not address the differing functionality that social media 
provides.110  While the documents were issued in the advent of social media, silence on the 
 
108 See Sorrell v. IMS Health, Inc., 564 U.S. 552, 571 (2011) (finding content- and- speaker 
based burdens on expression warrant heightened judicial scrutiny and subsequently applying 
Central Hudson to that effect); Pharmaceutical Research and Manufacturers of America, Draft 
Guidance for Industry on Internet/Social Media Platforms with Character Space Limitations 
(Docket No. FDA-2014-D0397), 8, n. 29 (Sept. 16, 2014) [hereinafter PhRMA Letter] 
(commenting that risk disclosures creates a speaker-based burden, subject to heightened scrutiny 
under Sorrell). 
109 The guidance relies heavily on section 201(n), but a reviewing court or industry challenge 
would likely assert mere probability of deception is insufficient.  See Cent. Hudson Gas & Elec. 
Corp. v. Pub. Serv. Comm’n of N.Y., 447 U.S. 557, 563 (1980) (“government may ban forms for 
communication more likely to deceive the public . . . .”) (emphasis added).  
110 See Cook Group, Inc., Docket No. FDA-2014-D-0447 Draft Guidance for Industry: 
Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation, 3 (Sept. 
16, 2014) [hereinafter Cook Letter] (commenting that the FDA should more “broadly reflect” the 
differing social media platforms that exist); Advanced Medical Technology Association, Docket 
No. FDA-2014-D-0397; Draft Guidance for Industry on Internet/Social Media Platforms with 
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matter since then provides room for amending or issuing new guidance to address the evolving 
platforms and address existing industry concerns.111 
B. The First Amendment 
1. Commercial Speech Doctrine 
Commercial speech protections were not readily recognized until Virginia State Board of 
Pharmacy v. Virginia Citizens Consumer Council, Inc.112  This case originated from a state law 
that prohibited pharmacists from publishing, advertising, or promoting information about the 
pricing of a prescription drug.113  Justice Blackmun found “society . . . may have a strong interest 
in the free flow of commercial information.”114  He observed that “the poor, the sick, and 
particularly the aged” are most afflicted by the hiding of prescription drug prices.115   
In recognizing the legal protection of commercial speech, Justice Blackmun offered that 
“we of course do not hold that it can never be regulated in any way.”116  He then listed typically 
 
Character Space Limitations, 2 (Sept. 16, 2014) [hereinafter AdvaMed Letter] (noting the FDA 
should take an approach that better reflects the “unique” attributes of social media).  
111 See infra Part III(B) (discussing how the FDA could issue new guidance to address this).  
112 425 U.S. 748, 770 (1976).  “Commercial Speech” is defined as “[c]ommunication (such as 
advertising and marketing) that involves only the commercial interests of the speaker and the 
audience . . . .”  Speech, BLACK’S LAW DICTIONARY (11th ed. 2019). 
113 425 U.S. at 749–50 (quoting VA. CODE ANN. § 54-524.35 (1974)).   
114 Id. at 764.  
115 Id. at 763.   
116 Id. at 770.  
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upheld restrictions, namely: those that are not content restrictive, serve an important government 
interest, or leave open ample alternative channels for communication.117  The lone dissenter, 
Justice Rehnquist, explained his disagreement with the majority, believing the First Amendment 
services “public decisionmaking as to political, social, and other public issues” and not the 
“purchase one or another kind of shampoo.”118 
This case has several important considerations for applicability to social media functions.  
First, Justice Blackmun recognizes that commercial speech is not immune to speech restrictions, 
which provides supportive language for the FDA to continue to regulate advertising and do so 
for information posted by a manufacturer on social media or equivocated through a function of 
social media.119  Justice Blackmun was keen to note that “society . . . may have a strong interest 
in the free flow of commercial information” and that, while advertising might be viewed as 
“excessive,” dissemination of this information is useful for consumer decisions.120  Social media 
 
117 Id. at 771. 
118 Id. at 787 (Rehnquist, J., dissenting).  Justice Rehnquist feared this ruling would go beyond 
simple display of price information, instead leading to “active promotion of prescription drugs, 
liquor, cigarettes, and other products . . . thought desirable to discourage.”  Id. at 781 (Rehnquist, 
J., dissenting).  See, e.g., Lorillard Tobacco Co. v. Reilly, 533 U.S. 525, 526 (2001) (striking 
down a law prohibiting outdoor and point-of-sale promotion of smokeless tobacco products and 
cigars); 44 Liquormart, Inc. v. Rhode Island, 517 U.S. 484, 516 (1996) (striking down a law 
prohibiting the promotion of liquor prices).  
119 Va. St. Bd. of Pharm., 425 U.S. at 770.   
120 Id. at 764–65. 
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can easily become a vehicle for these advertisements, which provides an important rationale for 
both industry and the FDA to come together and identify meaningful methods of regulation.121  
The signature test for commercial speech analysis came with Central Hudson Gas and 
Electric Corp. v. Public Service Commission of New York.122  The Court created a four-part legal 
inquiry into commercial speech restrictions.123  To evaluate the permissibility of a commercial 
speech burden, a court must first determine whether the speech is false or misleading.124  If the 
speech is found truthful and not misleading or concerns lawful activity, the court must find the 
government asserted a substantial interest.125  To sustain the speech restriction, the burden on 
speech must directly advance that interest and be no more extensive than necessary to achieve 
 
121 See infra Part III (explaining how the FDA can provide meaningful solutions and address 
existing industry concerns).  Justice Blackmun also highlighted the “the poor, the sick, and 
elderly” are often disproportionately affected by suppression of price information.  Va. St. Bd. of 
Pharm., 425 U.S. at 764.  With digital platforms becoming a cheaper alternative, there could be 
incentive for firms to reduce costs.  See Brent Gleeson, “TV Advertising vs. Digital Marketing,” 
FORBES (Nov. 20, 2012, 1:39 PM), https://www.forbes.com/sites/brentgleeson/2012/11/20/tv-
advertising-vs-digital-marketing/#2ee1129037f8 (stating some advantages to digital advertising 
are that it is cheaper and has better capacity to target specific consumer demographics). 
122 447 U.S. 557 (1980). 
123 Id. at 564, 572. 
124 Id. at 564.  
125 Id.  
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that interest.126  In practice, the protection will not apply if the speech in question is false or 
misleading.127  If the speech concerns lawful activity, is not misleading, and the government 
asserts a substantial interest, then the court must review whether the asserted interest is directly 
advanced by the regulation and whether it is more extensive than necessary.128 
Central Hudson is the oft cited case when a commercial speech restriction is at issue.129  
Addressing this case in guidance is imperative because it is a consistent topic industry mentions 
when there are limitations and requirements present in proposed guidance.130  Central Hudson 
 
126 Id.   
127 See Id. at 566 (identifying speech that is unlawful or misleading is not protected).  Recall a 
drug is misbranded if “its labeling is false or misleading in any particular.” FDCA § 502(a)(1), 
21 U.S.C. § 352(a)(1) (2018).  
128 Central Hudson, 447 U.S. at 566.  See, e.g., United States v. Caronia, 703 F.3d 149, 165–68 
(2d Cir. 2012) (applying Central Hudson’s test in this manner).  
129 See e.g., Thompson v. W. Sts. Med. Ctr., 535 U.S. 357 (2002) (challenging a provision of the 
Food and Drug Administration Act of 1997 that exempts compounded drug manufacturers from 
advertising); Lorillard Tobacco Co. v. Reilly, 533 U.S. 525 (2001) (challenging a statute 
prohibiting the advertising of tobacco and smokeless tobacco products); 44 Liquormart, Inc. v. 
Rhode Island, 517 U.S. 484 (1996) (challenging a state law prohibiting the advertising of alcohol 
prices); Rubin v. Coors Brewing Co., 514 U.S. 476 (1995) (challenging the Federal Alcohol 
Administration Act’s prohibition on beer labels displaying alcohol content). 
130 See WLF Letter, supra note 107, at 4–6 (discussing that the First Amendment jurisprudence 
grants constitutional protections to manufacturers); MIWG Letter, supra note 107, at 4. 
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can help aide the FDA because if the speech in question does not concern lawful activity or is 
misleading, it gives the FDA an opportunity to challenge the offending speech before needing to 
defend its limitations on speech.131  Additionally, the FDA can use guidance to offer alternative 
“channels” of communication on social media to show its restriction is not “more extensive than 
necessary.”132  Performing these actions would demonstrate that the FDA is crafting policy in a 
manner that shows it is trying to be as minimally restrictive as possible, a central element in 
reviewing commercial speech inquiries.133 
In the same vein of commercial speech, Sorrell v. IMS Health, Inc.134 articulated 
“heightened scrutiny” analysis applies when there are content- and speaker-based burdens on 
protected expression.135  This analysis is triggered by a “regulation of speech because of 
disagreement with the message it conveys.”136  To survive the inquiry, the state must 
 
131 Central Hudson, 447 U.S. at 566.  If the FDA can successfully prove the speech is unlawful 
or misleading, then the manufacturer that promoted its product in that manner will not be 
afforded First Amendment protection. Id.  
132 Id.; Va. St. Bd. of Pharm. v. Va. Citizens Consumer Council, Inc., 425 U.S. 748, 771 (1976).  
By doing this, the FDA can address First Amendment jurisprudence, which neither existing draft 
guidance does.  
133 See Central Hudson, 446 U.S. at 566 (where a court will review if the government’s 
restriction is more extensive than necessary). 
134 546 U.S. 552 (2011). 
135 Id. at 571 (2011). 
136 Id. at 566 (quoting Ward v. Rock Against Racism, 491 U.S. 781, 791 (1989)). 
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demonstrate “the statute directly advances a substantial government interest and that the measure 
is drawn to achieve that interest.”137  In Sorrell, the Court struck down a Vermont law that failed 
to meet this standard.138 While a small victory, the Court agreed that the public policy objectives 
of promoting public health and lowering the costs of medical services were “proper.”139   
This case has become foundational for its line “[s]peech in aid of pharmaceutical 
marketing, however, is a form of expression protected by . . . the First Amendment.”140  This line 
is now used against the FDA in both public comments on guidance as well as case law.141  
Neither existing guidance targeting social media makes mention of this principle, which is 
opportunity for improvement if the FDA decides to update these documents.142  Additionally, if 
the FDA creates new guidance or rules surrounding social media usage, Sorrell is important to 
address because its language appears inextricably linked to prescription drugs and 
 
137 This “ensure[s]” the burden is proportional to the government’s interest(s).  Id. at 572.  See 
also Central Hudson, 477 U.S. at 566 (listing the four-part intermediate scrutiny analysis). 
138 Sorrell. 564 U.S. at 557.  
139 Id. at 576.  
140 Id. at 557. 
141 See MIWG Letter, supra note 107, at 4 (commenting that the Character-Limit Guidance 
creates a prohibition on some firm’s trying to use character limited platforms in violation of 
Sorrell); infra Part II(C) (the cases discussing off-label promotion). 
142 Doing so could quell the concern of the FDA’s lack of position on how these documents 




representations made about them.143  If the FDA chooses to pursue more formal rulemaking 
related to prescription drug marketing on digital platforms broadly, this case certainly needs to 
be addressed.144  
2. Character Limit Guidance First Amendment Analysis 
It is useful to run the FDA’s current thinking through existing legal frameworks to 
evaluate whether it would stand under current precedent.  While the FDA notes what a firm 
“should” do, an enforcement action might be sufficient to trigger a First Amendment inquiry.145  
The predominant standards to consider here are Sorrell and the Central Hudson, four-step 
inquiry about commercial speech restrictions.146  The provision under review here is the FDA’s 
suggestion that firms who cannot meet the “fair balance” requirement “reconsider” using a 
platform with a character limit.147  A content-based burden on speech is created by enforcing 
 
143 See Sorrell v. IMS Health, Inc., 564 U.S. 552, 557 (2011) (“[s]peech in aid of pharmaceutical 
marketing . . . is a form of expression protected by the . . . First Amendment.”).   
144 If there is a regulation of speech based on content, “heightened scrutiny” is going to apply.  
Sorrell, 564 U.S. at 566; see infra Part III(B) (discussing how this could be done).   
145 See, e.g., Amarin Pharma, Inc. v. FDA, 119 F. Supp. 3d 196, 222 (S.D.N.Y. 2015) (where a 
warning letter sufficiently allowed Amarin to seek relief). 
146 See supra Part II(B)(1) (discussing the commercial speech doctrine). 
147 CHARACTER LIMIT GUIDANCE, supra note 10, at 5.  Additionally, this analysis is done as if the 
firm wants to use a “Product Claim” advertisement because the guidance was not intended to be 
used on “Reminder” advertisements. CHARACTER LIMIT GUIDANCE, supra note 10, at 4, n. 10.  
The “fair balance” requirement states that a firm must present information of comparable detail 
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that, in a character limited space, if a firm discusses the benefits it must also discuss the risks.148  
If a firm cannot meet such requirement, then it should avoid using the platform.149  The criteria 
used by a reviewing court will require the government to maintain a “substantial government 
interest” and that “the measure is drawn to achieve that interest” in addition to the other Central 
Hudson factors.150   
On the Central Hudson question of whether the speech is false or misleading, the FDA’s 
argument will be that tweets or other character limited posts are misleading because they do not 
adequately disclose sufficient risk information against the benefits.151  Industry will rebuke the 
FDA’s argument as impermissible because the FDA cannot restrict speech based on the notion 
that the speech is not more likely to deceive the public than not.152  Industry might invoke the 
 
between the side effects and contraindications and the effectiveness and safety.  Prescription 
Drug Advertisements, 21 C.F.R. § 202.1(e)(5)(ii) (2019). 
148 Sorrell, 564 U.S. at 565; § 202.1(e)(5)(ii). 
149 CHARACTER LIMIT GUIDANCE, supra note 10, at 5. 
150 Sorrell, 564 U.S. at 572 (stating how the government must justify its content-based burden 
and applying Central Hudson to evaluate that justification); see also Cent. Hudson Gas & Elec. 
Corp. v. Pub. Serv. Comm’n of N.Y., 447 U.S. 557, 566 (1980) (laying out the four-part 
commercial speech inquiry).  
151 FDCA § 201(n), 21 U.S.C. § 321(n) (2018) (omitting risk information is a failure to reveal a 
material fact); Central Hudson, 447 U.S. at 566. 
152 See also Thompson v. W. Sts. Med. Ctr., 535 U.S. 357, 367 (2002) (explaining Central 
Hudson does not apply if the speech concerns lawful activity and is not misleading); Central 
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FDA’s prior thinking about a reasonable consumer.153  They would argue under this concept that 
a single tweet demonstrating benefits and leaving either only the risks or a link to refer to them is 
not inherently misleading.154  Based on the language from the guidance and existing case law, 
the most applicable substantial government interest would be the protection of public health.155  
In defense of this interest, the FDA would assert that the FDCA’s purpose is to protect public 
health, that it should be afforded a “liberal construction,” and guidance is one of the informal 
tools it has to perpetuate that purpose.156 
 
Hudson, 447 U.S. at 563 (government may prohibit speech that is more likely to deceive the 
public than inform it). 
153 In a guidance document, the FDA entertained the “reasonable consumer standard.”  The 
standard looks through the eyes of a prospective consumer “acting reasonably in the 
circumstances.”  See U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: PRESENTING 
RISK INFORMATION IN PRESCRIPTION DRUG AND MEDICAL DEVICE PROMOTION 5 (2009) 
[hereinafter PRESENTING RISK INFORMATION GUIDANCE].  
154 Id. 
155 See id. at 576 (finding a policy objective of public health to be “proper”); United States v. 
Caronia, 703 F.3d 149, 166 (2d Cir. 2012) (finding that drug safety and public health are 
substantial interests); see also CHARACTER LIMIT GUIDANCE, supra note 10, at 5 (stating the 
public is best served through “truthful, non-misleading, and balanced” promotions). 
156 See United States v. An Article of Drug  . . . Bacto-Unidisk . . ., 394 U.S. 784, 798 (1969) 
(stating that a court should give “effect” to the congressional intent in making the FDCA with an 
“overriding purpose” of protecting the public health). 
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Even if a reviewing court upheld this interest, the next big challenge is determining 
whether the measure is drawn sufficiently.157  The guidance initially suggests that a firm seeking 
to discuss benefits must also discuss the risks associated with the drug.158  It also permits a 
manufacturer to use a link to expand upon the risks associated with the promoted drug, but it still 
must include risks in the character limited message.159  The FDA would argue that disclosure of 
information and a balanced presentation will best serve the public health.160  By requiring both a 
showing of the risks and a link addressing them further, that objective is achieved.  Further, they 
would assert that they have left “open ample alternative channels for communication of 
information” by allowing the risk discussion to continue elsewhere or simply allowing the firm 
to choose an alternative advertising platform.161  
 
157 In reviewing this element, the court is looking for a “fit between the legislature’s end and the 
means chosen to accomplish those ends.”  Sorrell, 564 U.S. at 572 (quoting Bd. of Trs. of St. U. 
of N.Y. v. Fox, 492 U.S. 469, 480 (1989)). 
158 CHARACTER LIMIT GUIDANCE, supra note 10, at 1. 
159 Id. at 10.  
160 See Va. St. Bd. of Pharm. v. Va. Citizens Consumer Council, Inc., 425 U.S. 748, 770 (1976) 
(discussing people will make the best choices when they have the information available to them); 
CHARACTER LIMIT GUIDANCE, supra note 10, at 5. 
161 Va. St. Bd. of Pharm., 564 U.S. at 771. 
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Conversely, industry would challenge that a listing of known risks and a link discussing 
them further is imbalanced.162  Further, it would similarly argue that the public health might be 
best served by simply only using a link for risk information because instead of a few words, 
consumers might be more willing to view an entire landing page than a tweet alone for the drug 
information.163  In doing so, they would contend under section 201(n) that they are revealing 
material facts about a drug because the link provides the information and is textually related to 
the article.164  Under statute and regulation, industry would also contend they are presenting 
more than a fair balance of the risks because a character-limited post containing a brief statement 
of benefit can be outweighed by a comprehensive discussion of the potential hazards under use 
provided within a link.165  In terms of a less restrictive means, industry would likely assert that 
 
162 See, e.g., PhRMA Letter, supra note 108, at 8–9 (stating that alternative means, such as using 
“introductory phrases” and providing a link or using a “universal graphic[al] symbols” could 
create a balanced presentation of information). 
163 A reasonable consumer under the circumstances might not consider a single tweet as the 
definitive authority on a drug’s information.  See PRESENTING RISK INFORMATION GUIDANCE, 
supra note 153, at 5 (articulating the standard for what a reasonable consumer does). 
164 FDCA § 201(n), 21 U.S.C. § 321(n) (2018).  This provision is also mentioned in the 
background of the guidance as a place where the guidance draws its strength. CHARACTER LIMIT 
GUIDANCE, supra note 10, at 3. 
165 See FDCA § 502(n)(3), 21 U.S.C. § 352(n)(3) (advertisements or other descriptive matter 
shall include information in brief summary pertaining to “side effects, contraindications, and 
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the “One-Click Rule” is a less burdensome alternative than guidance suggestion of both risks and 
a link, which could lead to the consequential decision of a firm “reconsider[ing]” use of the 
platform.166  The question will hinge on whether the content within the link satisfies the fair 
balance without the listing of the risks in the character-limited message.167   
C. Off-Label Promotion Roadblocks 
In a Second Circuit case, as the dissent puts it, “the majority calls into question the very 
foundations of our century-old system of drug regulation.”168  In statements made to a 
government informant, Mr. Caronia broadened the application of Xyrem beyond the contents of 
the approved labeling.169  Unfortunately for the FDA, the majority found Sorrell’s application of 
“heightened scrutiny” was warranted and the subsequent Central Hudson application yielded 
negative results for the agency.170  The court found that the prohibitions on off-label promotion 
 
effectiveness . . . .”); Prescription Drug Advertisements, 21 C.F.R. § 202.1(e)(5(ii) (2019) 
(violation of this regulation will not be found when presentation of information is comparable). 
166 CHARACTER LIMIT GUIDANCE, supra note 10, at 5.  The “One-Click Rule” was an industry 
developed initiative to provide a URL in a limited space to provide information instead of listing 
it all out.  See Randy Gray, Note, One Click is Enough: Satisfying FDA’s Fair Balance in the 
Highly-Regulated Marketplace, 39 RUTGERS COMPUTER & TECH. L.J. 95, 103–4 (2013); West, 
supra note 34, at 422. 
167 CHARACTER LIMIT GUIDANCE, supra note 10, at 5. 
168 United States v. Caronia, 704 F.3d 149, 169 (2d Cir. 2012) (Livingston, J., dissenting). 
169 Id. at 156–57. 
170 Id. at 164–69. 
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were content-based.171  The court also ruled that the restrictions were speaker-based because they 
targeted pharmaceutical manufacturers without restricting everyone else from discussing off-
label uses.172   
Perhaps most critical to potential issues related to social media promotion, under Central 
Hudson’s first element, the court found off-label promotion concerned lawful activity because 
off-label drug use is legal.173  It also stated that off-label drug promotion is “not in and of itself 
false or misleading.”174  While the FDA asserted the protection of the FDCA’s drug approval 
process as a substantial interest, the court reasoned the FDA was overly burdensome.175   
This problem for the FDA was further exacerbated a few years later with Amarin 
Pharma, Inc. v. United States Food and Drug Administration.176  Here, the court rejected the 
FDA’s argument that Caronia should be reviewed narrowly on its facts.177  Reemphasizing the 
Caronia decision, the Amarin court stated the “considered and firm view is that, under Caronia, 
 
171 Id. at 165.  
172 Id.  
173 Id.  Drugs go through extensive testing to reach FDA approval status and to claim that off-
label discussion is lawful strikes an interesting counterbalance.  See FDCA § 505(b)(1), 21 
U.S.C. § 355(b)(1) (2018) (FDA drug approval requirements).  
174 Caronia, 703 F.3d at 165.  
175 Id. at 167–68 (reasoning the government could educate physicians to discern information or 
develop a disclaimer system). 
176 119 F. Supp. 3d 196 (S.D.N.Y. 2015). 
177 Id. at 224. 
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the FDA may not bring such an action based on truthful promotional speech alone, consistent 
with the First Amendment.”178  The majority highlighted neither false nor misleading speech is 
protected and that expression, but not conduct, is protected.179 
 This opinion highlights an integral challenge the FDA faces: protected expression.180  
This makes the FDA’s regulatory job harder with respect to social media functions because 
retweeting or sharing a post from a consumer in support of a product, even if the content is off-
label, will likely result in a comprehensive First Amendment analysis.181  While Amarin finds 
that “Caronia leaves room for prosecuting off-label marketing as misbranding,” it still seems to 
narrow the gap the FDA could prosecute by also stating “a manufacturer that engages in non-
communicative activities . . . cannot use the First Amendment as a shield.”182  A manufacturer 
could raise that a post that is shared, retweeted, or liked is a communicative activity, and 
therefore, behind a First Amendment shield. 
 
178 Id.  
179 Id. at 228. 
180 Id.  
181 This could be argued as expression in pursuit of pharmaceutical marketing, bringing it under 
the umbrella of protection.  See Sorrell v. IMS Health, Inc., 546 U.S. 552, 557 (2011) (“[s]peech 
in aid of pharmaceutical marketing, however, is a form of expression protected by . . . the First 
Amendment”); United States v. Caronia, 704 F.3d 149, 161–62 (2d Cir. 2012) (prosecution of an 
individual for aiding pharmaceutical marketing). 




Social media is an evolving platform that shifts the way people and business can interact.  
To some extent, there is a hidden genius to the FDA remaining silent on the subject for so long.  
It could be the sole reason there has not been a proliferation of advertising for prescription drugs 
on your Facebook page.183  However, industry will not remain idle as these sites and apps 
become more attractive for reaching consumers.184  Facebook used to be just a place for people 
to post their own thoughts and share articles or media.  Now, it has a marketplace where 
businesses and people can post goods and services they have for sale.185  These types of 
technological evolutions in social media spaces might continue and business are attracted to it.186  
The FDA should see this as an opportunity to update existing regulations and issue more 
guidance in furtherance of its statutory calling.  The following analyses will explore how the 
FDA should consider social media functions in advertising and how this thinking could apply to 
promulgating updated or new guidance issuances and rulemaking.  
 
183 Kassity Liu, FDA and Social Media: The Impact of Social Media on Prescription Drug 
Advertising, Jolt Dig. (Apr. 17, 2012), https://jolt.law.harvard.edu/digest/fda-and-social-media-
the-impact-of-social-media-on-prescription-drug-advertisin.  
184 Tiku, supra note 3.  
185 About Marketplace for Business, FACEBOOK, (last visited July 11, 2020) 
https://www.facebook.com/business/help/289268564912664?id=150605362430228. 
186 Tiku, supra note 3. 
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A. Social Media Functions and Advertising 
The FDA should directly address the functions of social media platforms to clarify the 
regulatory gap that exists.187  To begin, it should invoke the FDCA and Kordel as authority over 
such communications.188  It should continue to take an expansive view of the labeling provisions 
because communications about an article ultimately supplement the article, which can 
synchronously function as advertising information since the FDCA also addresses advertising in 
a similar manner.189  For example, the FDA should indicate if a company “likes” or “retweets” a 
statement about a product, that symbolic gesture should indicate the contents of the post 
“accompany such article” consistent with the content of the affirmed post.190  This should be 
seen as a “representation” of the product because it can evince an intent about a firm’s 
 
187 See, e.g., Prescription Drug Advertisements, § 202.1 (2019) (where social media is not 
addressed, or the words “digital,” “internet,” and “online” do not appear either).  
188 See FDCA § 201(n), 21 U.S.C. § 321(n) (2018); 335 U.S. 345, 350 (1948) (holding the 
textual relationship matters). 
189 See FDCA § 201(m), (n) 21 U.S.C. 321(m), (n) (in considering whether there is a 
misbranding, the labeling or advertising shall be considered to evaluate the representations made 
about the product); Kordel v. United States, 335 U.S. 345, 349 (1948) (finding that an article is 
accompanied when something “supplements or explains it.”).  See also PRESENTING RISK 
INFORMATION GUIDANCE, supra note 153, n. 9 (defining “promotional piece, promotional 
materials, and promotional communications” to include Internet web sites).  
190 FDCA § 201(m), 21 U.S.C. § 321(m) (where labeling means “all written, printed or graphic 
matter . . . accompanying such article”).   
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understanding and beliefs about the product since it reaffirms one of its consumers endorsements 
or other representations related to its use.191  If the post being “liked” or “retweeted” is in relation 
to a use off-label, then a misbranding action could be brought against the firm.192 
If the source of the firm’s engagement appears in a comment or user reply where 
character limits are not a concern, then the FDCA and paired regulations provide the FDA with a 
strong framework for regulating such representations.193  Under FDCA § 502(n)(3), for example, 
the firm must provide the “brief summary” of the drug and if limits are of no concern, then the 
inclusion of such should be required.194  These regulations should become more feasible because 
in a space where one can place text and other media, without constraint, satisfying this 
 
191 Id.; FDCA § 201(n), 21 U.S.C. § 321(n) (“there shall be taken into account . . . 
representations made or suggested by statement, word, design, device, or any combination 
thereof” in consideration of misbranding).  See generally Chang Zhou, Consumers as Marketers: 
An Analysis of the Facebook “Like” Feature as an Endorsement, 41 W. ST. U.L. REV. 115, 117–
18, 126–129 (2014) (arguing how the “like” feature on Facebook could operate as an 
endorsement under the Federal Trade Commission Act and related guides).    
192 FDCA §§ 301(a), 502(a)(1), 21 U.S.C. §§ 331(a), 352(a)(1) (introducing into interstate 
commerce a drug that is misbranded is a prohibited act). See also Amarin Pharma, Inc. v. U.S. 
Food & Drug Admin., 119 F. Supp. 3d 196, 228 (2015) (holding Caronia leaves room for off-
label marketing to be considered misbranding).  
193 See FDCA §§ 201(m), (n), 502(n), 21 U.S.C. §§ 321(m), (n), 352(n). 
194 FDCA § 502(n)(3), 21 U.S.C. § 352(n)(3).  The requirements for how to meet this are 
expounded on in the CFR. Prescription Drug Advertisements, 21 C.F.R. § 202.1(e)(1) (2019). 
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requirement should be simple.  Similar to the objectives of the third-party misinformation 
guidance, a comment section provides opportunity to correct statements made about a product to 
be consistent with the FDA approved labeling.195  Further, these limits provide firms the ability 
to adequately clarify or specify important information, which can help shield from potential 
misbranding violations that might arise from terse or unclear comments.196  
The off-label promotion jurisprudence thus far does create some important concerns for 
the FDA to monitor.197  Whereas Wisconsin v. Mitchell held the “First Amendment . . . does not 
prohibit the evidentiary use of speech to establish elements of a crime,” Caronia offered stark 
contrast, instead, prohibiting the FDA from doing as such.198  The best hope for the FDA in this 
dichotomy is that the Supreme Court rejects Caronia or at least the Second Circuit overrules 
itself with other circuits declining to accept the holding.  However, a trend seems to indicate 
whenever the means by which the government seeks to achieve its substantial interest in the 
sphere of drug regulation, the reviewing court finds less restrictive means that could be 
 
195 THIRD-PARTY MISINFORMATION GUIDANCE, supra note 10, at 1. 
196 See FDCA §§ 201(n), 502(a)(1), 21 U.S.C. §§ 321(n), 352(a)(1) (elaboration could help 
ensure the drug is not misbranded from terse and unclear statements about it). 
197 Supra Part II(C). 
198 See 508 U.S. 476, 489 (1993); United States v. Caronia, 703 F.3d 149, 169 (2d Cir. 2012) 
(Livingston, J., dissenting).  But see Caronia, 703 F.3d at 162, 165 (concluding the government’s 
prosecution of Mr. Caronia for his speech did not comport with the First Amendment). 
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employed, or an exception is carved out.199  These precedents seem to have eroded the 
government’s capacity to win on the first element of Central Hudson.200 
Nonetheless, the FDA should incorporate a direct discussion about how social media 
functions can lead to a drug becoming misbranded.201  Since social media provides the ability to 
use differing forms of media, this can create a diverse array of options for which the FDA can 
evaluate claims made by a company.202  An example could be for video mediums, like Snapchat, 
advertising videos that illustrate someone using a drug for an indication unapproved by the FDA 
could be grounds for a misbranding action, especially if the post also provides a link to 
information unsupported by the FDA labeling.203  If a firm repeatedly likes and shares customer 
testimonials, without influencing or soliciting the information, then the FDA might find the 
product as a “new drug” that, unsupported by an approved FDA application, is illegal.204 
 
199 See supra Part II(B) (exploring the First Amendment jurisprudence and drug intersections). 
200 See supra Part II(C) (discussing that discussion of off-label information is not necessarily 
unlawful or misleading); Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n of N.Y., 447 
U.S. 557, 566 (1980) (inquiring whether the challenged speech burden concerns lawful activity).  
201 FDCA § 201(m), (n), 21 U.S.C. § 321(m), (n). 
202 Id.  
203 See FDCA §§ 201(n), 502(a), 21 U.S.C. §§ 321(n) (considering the representations made), 
352(a) (labeling becoming false because of inconsistency with the approved labeling). 
204 FDCA §§ 201(p), 505(a), 21 U.S.C. §§ 321(p), 355(a). 
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B. Issuing Further and Updated Guidance Documents 
The FDA should update or issue final guidance on the presently titled social media 
guidance documents.  Six years of public availability should present a reasonable window of 
time to update existing thinking.  Industry has shared its perspective on the guidance documents 
and found several problems.205  First Amendment issues, especially Sorrell, were a major source 
of concern over the character limit guidance.206  Since the FDA failed to address the First 
Amendment in its current thinking, it should update existing guidance to include a discussion of 
this.  Central Hudson and Sorrell should be the focus since they lay the foundation for review.207 
For the third-party misinformation guidance, the FDA should permit the corrective 
material to be promotional in nature.  This serves the purpose of becoming less-restrictive than 
necessary and would give creative latitude to manufacturers to send corrective information using 
 
205 See WLF Letter, supra note 107, at 8, 11, 15 (exploring how the character limit guidance is 
overly broadens FDA authority and constrains speech); MIWG Letter, supra note 107 (exploring 
the failure to account for Sorrell); PhRMA Letter, supra note 108, at 5 (noting that heightened 
scrutiny will apply). 
206 See WLF Letter, supra note 107; MIWG Letter, supra note 107; PhRMA Letter, supra note 
108. 
207 See supra Part II(B)(1) (discussing the commercial speech doctrine and when burdens on 
speech call for analysis). 
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advertisements containing either the major statement or brief summary for the prescription drug 
that needs its information corrected in a medium.208  
In taking the path to update the character limit guidance, it should consider adopting less-
restrictive means and include the First Amendment jurisprudence.  For instance, it should 
consider lightening up the suggestion that a firm incorporate both important risks and a URL to 
address them further.209  Industry offers a good suggestion for the adoption of universal 
iconography, which could make research easier on the consumer.210  It could pair this with the 
creation of its own education materials for consumers to teach them the important aspects of 
drug labeling and advertising and what to look for.211  This will serve an important purpose for 
the First Amendment jurisprudence because the courts have continued to find ways the 
government could be less restrictive when creating burdens on speech.212  To address this case, 
 
208 For example, a company could have a television advertisement or a direct copy of a magazine 
ad it ran, which would need to comport with the “brief summary” or “major statement” 
requirement.  FDCA § 502(n), 21 U.S.C. §352(n); see Cent. Hudson Gas & Elec. Corp. v. Pub. 
Serv. Comm’n of N.Y., 447 U.S. 557, 564 (1980) (government restriction cannot be more 
burdensome than necessary). 
209 See CHARACTER LIMIT GUIDANCE, supra note 10, at 10 (suggesting the inclusion of a URL to 
help comprehensively address the totality of the risk information).  
210 PhRMA Letter, supra note 108, at 8–9.  
211 See, e.g., United States v. Caronia, 703 F.3d 149, 167–68 (2d Cir. 2012) (finding the 
government could address off-label promotion through education programs). 
212 Id.  
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the FDA should continue to explain that the public health is the core of its rationale for providing 
such guidance.213  If it is going to suggest a firm not use a particular platform due to inability to 
meet the “fair balance” requirement, it should afford thinking as to why the suggested 
prohibition is permissible and give explanation to alternative means for the firm to use.214  In 
doing so, the FDA would take into account both Sorrell and Central Hudson by explaining the 
measures taken are “not more extensive than necessary” to achieve the protection of the public 
health.215  The use of a link in addition to the risk information poses one of the places for 
elaborating on this thinking.216  In addition to how character-limited spaces might impact a 
consumer becoming misled, the guidance should incorporate consumer studies to help provide 
further guidance and context for what factors most directly contribute to consumer 
understandings.217 
 
213 See CHARACTER LIMIT GUIDANCE, supra note 10, at 5 (emphasizing the public health is best 
served by clear information).  
214 Industry might be successful in arguing that prohibition on a character-limited platform would 
violate principles of “leav[ing] open ample alternative channels” because it is a chilling effect on 
an entire type of platform. Va. St. Bd. of Pharm. v. Va. Citizens Consumer Council, Inc., 425 
U.S. 748, 771 (1976). 
215 Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n of N.Y., 447 U.S. 557, 566 (1980). 
216 See supra Part II(B)(2) (exploring how commercial speech restrictions could be less 
burdensome using a link instead of a balanced representation of risk and benefit information). 
217 While statute permits the FDA to evaluate misbranding based on material omission, a clearer 
discussion of factors to look for would benefit both industry in crafting better advertisements, but 
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The FDA should take this as an opportunity to provide new and direct guidance about 
how it believes user interactions will fall within the scope of the FDCA.  For example, new 
guidance could explain that liking posts about a product creates a “textual relationship” that can 
be considered reviewed in a misbranding action.218  Videos that can reach the same length as 
other broadcast mediums can also fall under the same guidelines imposed on those mediums.219   
New guidance could also address how DTC advertising and using targeted advertising tools on 
social media could be regulated.220  For instance, the FDA explore how demographic tools 
among other factors could lead to a drug becoming misbranded because the promotion of such 
drug is “false or misleading” because the targeted group of individuals is not within the scope of 
the FDA approved labeling.221  It could also directly address First Amendment jurisprudence 
because the first element of Central Hudson does not protect speech that is not truthful or 
misleading.222 
 
also meet potential legal hurdles related to a court determining if the language is definitively 
misleading.  See FDCA § 201(n), 21 U.S.C. § 321(n) (2018); Central Hudson, 447 U.S. at 563 
(government may ban speech more likely to deceive than not).  
218 United States v. Kordel, 335 U.S. 345, 350 (1948); supra Part III(A).  
219 Recall Snapchat allows advertisements of 3 to 180 seconds in either images or video. “Single 
Image or Video Ads,” supra note 17. 
220 See Tiku, supra note 3 (noting the concerns both manufacturers and consumers have about 
targeted advertising).  
221 FDCA § 502(a)(1), 21 U.S.C. § 352(a)(1) (2018).  
222 Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n of N.Y., 447 U.S. 557, 566 (1980). 
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Additionally, this creates a prime opportunity to obtain comments on its statutory and 
case law interpretations.  In the wake of either new or updated guidance, this is a chance for 
government and industry to come together and grapple with these developing platforms.  The 
FDA should consider reaching out to the creators of these platforms to gather developer insights 
for what these social media platforms can achieve in order to create effective rules or guidance 
that can address a lasting and evolving system.  Like the growth of radio and television, which 
have run alongside print, this new medium seems to combine the two and the FDA should not 
continue to let it grow without documenting some form of updated thinking. 
C. Notice-and-Comment Rulemaking  
Notice-and-comment rulemaking could be a more effective tool to promulgate new 
regulations for governing social media tools.  The APA provides agencies the ability to create 
“rules” in furtherance of their statutory calling.223  Unlike the guidance exemption, this route also 
provides something that guidance documents do not: a rule with a force of law.224  However, the 
agency must adhere to several formalities.225  Summarily, an agency must provide the public 
with an opportunity to comment on a proposed rule and consider such comments in promulgation 
of the final rule.226   
 
223 A “rule” under the APA means “the whole or a part of an agency statement of general or 
particular applicability and future effect designed to implement, interpret, or prescribe law or 
policy . . . .” APA, 5 U.S.C. § 551(4) (2018) (emphasis added).   
224 APA, § 551(4). 
225 APA, § 553.  See supra Part II(A) (explaining the guidance exception). 
226 APA, § 553(c).  A rule cannot be effective within thirty days of initial notice.  APA, § 553(d). 
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In using this method to address social media functionality, the FDA should update 
existing regulations to include social media and digital advertising.  As an example, in the 
“Prescription Drug Advertisements” regulation, the current provision of the act provides 
“Advertisements subject to section 502(n) of the act include advertisements in published 
journals, magazines, other periodicals, and newspapers, and advertisements broadcast through 
media such as radio, television, and telephone communication systems.”227  The FDA should 
address this section of the CFR to include digital platforms and include language that names 
social media as an example.  Another opportunity for update comes in the next subsection, which 
lists different types of descriptive matter the FDA deems to be “labeling” under the FDCA.228  
While it comes close to identifying digital and social media items with “similar pieces of printed, 
audio, or visual matter descriptive of a drug,” it could stand to benefit from a clearer definition 
that “similar pieces” include digital advertisements and labeling of the drug.229  
The usage of notice-and-comment rulemaking has several benefits for the FDA and 
industry.  One such advantage is the public process for issuing comments.230  By utilizing this 
process, the FDA can obtain documented feedback for its current vacuum in social media 
regulation by reviewing how industry believes the agency can proceed.  Another advantage to 
this process is that social media platforms could also provide comments and information about 
 
227 Prescription Drug Advertisements, 21 C.F.R. § 202.1(l)(1) (2019). 
228 It provides that items like brochures, bulletins, and literature, among other things, are 
considered labeling. § 202.1(l)(2). 
229 Id.  
230 APA, § 553(c). 
48 
 
how their platform could contribute to the success of the FDA’s progress in creating effective 
policy.231  This highly visible public process encourages accountability, which was fundamental 
in the passage of the APA.232  In the public sphere, industry benefits from this accountability 
because the FDA must consider its comments.233  The FDA wins from this accountability 
because it gets a second-mover advantage of receiving this feedback and earning the opportunity 
to consider and craft around the major concerns offered by the public.234  However, significant 
challenges exist, like the costs associated with crafting, publicizing, and finalizing review of a 
proposed rule.235  Further, input by individuals who are not directly regulated by agency rules 
may not provide input, leading the agency to bend toward only the regulated interest and not the 
 
231 For example, discuss how targeted advertisements work on a specific platform. See Tiku, 
supra note 3 (discussing targeted advertising concerns).  
232 See S. Rep. No. 79-752, at 8 (1945) (“[referencing the public information section] [t]he 
section has been drawn upon the theory that administrative operations and procedures are public 
property which the general public, rather than a few specialists or lobbyists, is entitled to know 
or to have the ready means of knowing with definiteness and assurance”). 
233 APA, § 553(c). 
234 Id.  
235 See David Fontana, Reforming the Administrative Procedure Act: Democracy Index 
Rulemaking, 74 FORDHAM L. REV. 81, 84–85 (2005) (exploring challenges presented with 
notice-and-comment rulemaking).  
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public at-large.236  Despite these costs, the ability to create a regulation with the force of law 
provides significant value in furthering the agency’s statutory calling.237 
CONCLUSION 
 The advent of social media has proliferated and amalgamized itself to be a massive force 
in the future of the digital age.238  Digital advertising expenditures by the pharmaceutical 
industry demonstrates a financial testament to the importance of advertising.239  With a drug 
approval process that is both rigorous and expensive, companies finding more attractive ways to 
promote products will remain a priority.240  By adhering to statutory provisions and updating 
existing regulations and thinking on the topic, the FDA will be able to successfully create and 
enforce guidelines designed to promote the public health.  By doing so, the FDA will make 
significant headway in the rapidly developing digital age.  In promulgating these regulations or 
issuing guidance documents, the FDA should make the concerted effort to address existing First 
 
236 Id. at 85 (FDA rulemakings showed greater participation by regulated interests according to a 
1977 study).  
237 APA, § 551(4). 
238 See Clement, supra note 14 (social media platforms have tremendous user bases). 
239 Benes, supra note 9. 
240 See Hutt, supra note 23, at 643 (noting approval for a new chemical entity can cost upwards 
of $2 billion over fifteen years); Keith B. Leffler, Persuasion or Information? The Economics of 
Prescription Drug Advertising, 24 J.L. & ECON. 45, 74 (1981) (concluding that promoting a 
newly developed product has a significant effect on the success of a new drug). 
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Amendment issues that have begun proliferating.241  By implementing an approach that 
demonstrates it is not trying to be unduly burdensome, the FDA should be able to place itself in a 
position to thwart challenges while still implementing effective new policies in prescription drug 
advertising regulations.242 
 
241 See supra Part II(C) (discussing the off-label promotion roadblocks). 
242 See supra Parts II(B), III(B) (emphasizing the importance of less-burdensome alternatives in 
case law and how the FDA could consider navigating this requirement).  
